The Clinical Research On The Treatment Of Dampness-heat Blockage Type To Ankylosing Spondylitis With Xuan Bi Decoction

Objective:Observe the clinical efficacy and safety of Xuanbi Decoction for treating damp-heat paralysis-type ankylosing spondylitis(AS),and explore the effective treatment of AS with integrated Chinese and Western medicine.Methods:The study subjects were a total of 60 patients treated in the outpatient department and inpatient department of the Department of Orthopaedics,People's Hospital of Fujian University of Chinese Medicine from July 2017 to July 2019.Western medicine was diagnosed as ankylosing spondylitis and was active,and TCM syndrome was diagnosed as damp-heat paralysis type.The patients were randomly divided into two groups of 30 cases each,in which the control group was given celecoxib + sulfasalazine,and the experimental group was given Xuanbi Decoction+ celecoxib + sulfasalazine.The course of treatment was 6months.Observe and record the BASDAI,BASFI,BASMI,spinal pain,total patient evaluation,ESR,CRP,PLT,BASRI-hip,TCM symptom score and other adverse reactions in two groups of patients,determine the clinical efficacy after treatment and apply SPSS21.0Software to perform statistical analysis on the obtained data.results:1.A total of 60 patients were included in this subject,4 patients were shed,28 patients in the final control group and 28 patients in the experimental group.There was no statistical difference between the two groups in the general situation before treatment(P> 0.05),which are comparable.2.BASDAI,BASFI,BASMI,spinal pain,overall patient evaluation: After treatment,BASDAI,BASFI,BASMI,spinal pain,and overall patient evaluation were significantly different from those before treatment in this group(P <0.05).Compared with the control group,the experimental group had significant differences in the observation indexes of BASDAI,BASFI,BASMI,spinal pain,and overall patient evaluation(P <0.05).3.ESR,CRP,PLT:After 3 and 6 months of treatment,the ESR,CRP,and PLT of the two groups were lower than those before treatment(P <0.05).After 3 and 6 months of treatment,the ESR,CRP,and PLTof the experimental group were significantly lower than those of the control group(P <0.05).4.BASRI-hip score: There were no significant differences in BASRI-hip scores between the two groups of patients before and after treatment and between groups(P> 0.05).5.TCM syndrome points: After 6 months of treatment,the TCM syndrome points of the two groups were significantly lower than before treatment(P <0.05);after 6 months of treatment,the TCM syndrome points of the experimental group were significantly lower than the control group(P <0.05).6.The efficacy of TCM syndromes: after treatment for 6 months,the total effective rate in the experimental group was 92.86%,and the total effective rate in the control group was64.29%.There was a significant difference by statistical test(P <0.05),and the experimental group was better than the control group.7.ASAS20 efficacy: After 6 months of treatment,the compliance rate of the experimental group was 85.71%,and the control group was 60.71%.There were significant differences by statistical test(P <0.05).The experimental group was better than the control group.8.Adverse reactions: After treatment,the incidence of adverse reactions in the experimental group was 10.71%,and the incidence of adverse reactions in the control group was 17.86%.The occurrence of adverse reactions in the two groups of patients was not significantly different by chi-square test(P> 0.05).Conclusions: Xuanbi decoction combined with celecoxib and sulfasalazine to treat damp-heat block ankylosing spondylitis can significantly reduce the patient's symptoms,improve signs,reduce the level of inflammatory indicators,help improve clinical efficacy,and in the treatment process No obvious adverse reactions were found in the test.